Q4 Earnings Estimate for BLFS Issued By Northland Capmk

BioLife Solutions, Inc. (NASDAQ:BLFS) – Northland Capmk issued their Q4 2025 earnings per share (EPS) estimates for BioLife Solutions in a research note issued on Wednesday, January 8th. Northland Capmk analyst C. Byrnes forecasts that the medical equipment provider will post earnings of $0.00 per share for the quarter. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. Northland Capmk also issued estimates for BioLife Solutions’ FY2026 earnings at $0.10 EPS.

Other equities research analysts have also issued reports about the stock. TD Cowen raised their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Craig Hallum lifted their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Benchmark reiterated a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. HC Wainwright decreased their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, KeyCorp increased their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Stock Down 3.9 %

Shares of NASDAQ:BLFS opened at $26.61 on Friday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a fifty-two week low of $14.50 and a fifty-two week high of $28.88. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -25.10 and a beta of 1.92. The firm’s 50 day moving average price is $25.99 and its 200 day moving average price is $24.29.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter worth $28,000. Quest Partners LLC purchased a new position in BioLife Solutions in the third quarter valued at about $57,000. GAMMA Investing LLC increased its holdings in BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of BioLife Solutions during the 2nd quarter valued at approximately $122,000. Finally, Arizona State Retirement System purchased a new stake in shares of BioLife Solutions during the 2nd quarter worth approximately $217,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other BioLife Solutions news, CEO Greef Roderick De sold 46,896 shares of the stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $23.43, for a total transaction of $1,098,773.28. Following the completion of the sale, the chief executive officer now directly owns 414,958 shares of the company’s stock, valued at approximately $9,722,465.94. This trade represents a 10.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now owns 121,779 shares of the company’s stock, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,129 shares of company stock valued at $2,576,818. 2.20% of the stock is currently owned by company insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.